Fiji

Reimbursed Care Access

Fiji maintains a restrictive national drugs framework under the Illicit Drugs Control Act (2004) that criminalises possession, importation, manufacture and supply of listed ’illicit drugs’ while permitting conventional medical use of recognised anaesthetics such as ketamine. There is no evidence of authorised medical registration or public reimbursement pathways in Fiji for modern psychedelic therapeutics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, mescaline, 2C‑X) or for marketed esketamine products; access outside clinical research is effectively prohibited for those substances. The government has recently emphasised a strong supply‑reduction and enforcement approach in its national counter‑narcotics strategy. [https://www.health.gov.fj/wp-content/uploads/2018/02/Fiji-Illicit-Drug-Act-2004.pdf|Fiji Illicit Drugs Control Act 2004] [https://www.fiji.gov.fj/Media-Centre/News/NATIONAL-DRUG-AND-NARCOTIC-STRATEGY-TO-COMBAT-DRUG|Fiji Government - National Drug & Narcotic Strategy 2023-28].